Delivery Order SPE2DB20D3103-SPE2DB22FP6X8
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,031.56, is for the delivery of 20,000 unit vials of Thrombin-JMI, a medical product used for surgical procedures. This is a firm fixed-price delivery order contract with a completion date of September 16, 2022. The contract does not have a set-aside designation, indicating open competition....
- This federal contract award, with a ceiling value of $41,040.20, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of 20,000 unit vials of Thrombin-JMI, a pharmaceutical product, with a performance period extending through May 9, 2025. This contract is not set-aside and is awarded as a firm-fixed-price contract. AmerisourceBergen Drug Corp holds a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,470.00 firm fixed-price delivery order is for the supply of 20,000 unit vials of Thrombin-JMI, a medical product used in various healthcare applications. The award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
- This federal contract award, valued at $7,902.12, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 20,000 unit vials of Thrombin-JMI, a medical product, with a performance period ending on January 31, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,739.44 firm fixed-price delivery order is for the supply of 20,000 unit vials of Thrombin-JMI, a specialized blood coagulant product. This order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 through November 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 22, 2026, for the supply of Thrombin-JMI 20,000 unit vials valued at $27,094.51 with a completion date of January 23, 2026. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 22, 2026, for the supply of Thrombin-JMI 5,000 Units Vials, a pharmaceutical product used in surgical hemostasis and wound management. This firm fixed-price delivery order has a ceiling value of $1,524.48 and an ultimate completion date of January 23, 2026, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a non-set-aside, competitive basis,...
- This federal contract award, valued at $5,207.93, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 20,000 unit vials of RECOTHROM, a branded medical product, with a completion date of July 26, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999, which serves as a primary vehicle for AmerisourceBergen to...
- This federal contract award is a delivery order with a firm fixed price valued at $4,922.29, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for RECOTHROM 20,000 unit vials, a medical product, with a completion date of June 10, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and running through...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,139.43 Firm Fixed Price contract is for the delivery of 20,000 unit vials of the specialty medication RECOTHROM. This award is a Delivery Order under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive range...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB22FP6X8Delivery Order
This federal contract award, valued at $12,472.32, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4558286079 - THROMBIN-JMI 20,000 UNIT VIALS and has an ultimate completion date of August 31, 2022. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. AmerisourceBergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. The contract awarded does not have a set-aside designation, indicating open competition. No subcontractors were mentioned in the provided information.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 8/30/22 |